Friday, November 13, 2026

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), ExxonMobil Holdings Corp. (XOM) and Pfizer Inc. (PFE). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> PPI +6.5% YoY: Highest in Nearly 4 Years

Today's Featured Research Reports

Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past year (+28.4% vs. +10.5%). Per the Zacks analyst, the company benefits from its strong global brand, extensive payments network and growth in digital transactions, cross-border payments and commercial solutions. Investments in agentic commerce, stablecoin settlement and strategic acquisitions should further strengthen its competitive position.

However, rising client incentives and marketing expenses are pressuring profitability. Uneven cash activity across regions, elevated valuation and persistent regulatory and litigation risks remain concerns.

(You can read the full research report on Visa here >>>)

ExxonMobil’s shares have outperformed the Oil and Gas - Integrated - International industry over the past six months (+12.6% vs. +8.3%). The Zacks analyst believes that the company benefits from low-cost production, an integrated business model and expansion opportunities in the Permian, Guyana and global gas markets. Technological innovation, cost discipline and higher-value products strengthen efficiency and long-term competitiveness.

Yet, exposure to commodity price volatility and changing energy demand remains a concern. Large-scale project execution and the energy transition also pose operational and strategic challenges.

(You can read the full research report on ExxonMobil here >>>)

Pfizer’s shares have underperformed the Large Cap Pharmaceuticals  industry over the past year (+22.8% vs. +33.7%). The Zacks analyst believes that the company faces significant patent expiration risks, while its near-term growth outlook remains subdued. Revenue pressure from losing exclusivity on key products could weigh on performance.

However, improving non-COVID product sales, new launches and acquisitions are supporting recovery. Pipeline investments in oncology and obesity offer longer-term growth opportunities, while its recent earnings surprise track record provides some encouragement.

(You can read the full research report on Pfizer here >>>)

Other noteworthy reports we are featuring today include U.S. Bancorp (USB), Blackstone Inc. (BX) and Edwards Lifesciences Corp. (EW).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>